Vir Biotechnology

Vir Biotechnology

World Rank (Aug-2026)
7286
Market Cap (Aug-2026)
1.564 Billion USD
Market Cap (Mar-08-2026)
1.332 Billion USD
World Rank (Jan-05-2024)
7,125
Market Cap (Jan-05-2024)
1.382 Billion USD
World Rank (Jul-30-2023)
5,935
Market Cap (Jul-30-2023)
1.894 Billion USD
World Rank (Jan-07-2022)
3,617
Market Cap (Jan-07-2022)
4.401 Billion USD
World Rank (Jan-01-2021)
3,943
Market Cap (Jan-01-2021)
3.411 Billion USD
Headquarters Country
USA
Top Healthcare Companies in USA
Nasdaq / NYSE Code
VIR
Employee Count
444
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
69 Million USD
Annual Operating Income in USD
-479 Million USD
Annual Net Income in USD
-438 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
1,003 Million USD
Total Liabilities in USD
238 Million USD
Total Equity in USD
765 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Company Website
VIR BIOTECHNOLOGY
Yahoo
Yahoo @ Nasdaq
Company Profile

Vir Biotechnology is a Clinical Stage Immunology company. It is focused on combining immunologic insights with cutting edge technologies to treat and prevent serious infectious diseases. The headquarters is in USA.

Annual Results Summary

VIR BIOTECHNOLOGY - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-20221,580833515
Dec-20211,095 420 528
Dec-202076 -296 (Loss)-298 (Loss)
Dec-20198-177 (Loss)-174 (Loss)
Dec-201810 -118 (Loss)-115 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 2,802 Million USD.

Total Liabilities as on Dec-2022 was 724 Million USD.

Total Equity as on Dec-2022 was 2,077 Million USD

Founded Year
2016
IPO Year
2019
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share